Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Roy Fleischmann¹, Yusuf Yazici², Jürgen Wollenhaupt³, Lisy Wang⁴, Anna Maniccia⁵, Kenneth Kwok⁴, Liza Takiya⁵ and Ronald van Vollenhoven⁶, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²New York University Hospital for Joint Diseases, New York, NY, ³Teaching Hospital of the University of Hamburg, Schoen-Klinik Hamburg-Eilbek, Hamburg, Germany, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…
Abstract Number: 2680 • 2015 ACR/ARHP Annual Meeting
Severity of Morning Stiffness Is Associated More Strongly with Disease Activity in Patients with Rheumatoid Arthritis
Belén Barrios¹, Rafael Chaparro del Moral², Oscar Luis Rillo², Silvia Beatriz Papasidero¹, María Alejandra Medina², Sergio Paira³ and Carolina Sandobal⁴, ¹Rheumatology Department, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ²Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁴Hospital Jose Maria Cullen, Santa Fe, Argentina
Morning stiffness (MS) is a complex symptom involving pain and functional limitation. It is not included in the ACR/EULAR 2010 classification criteria for rheumatoid arthritis…
Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld² and Mona Trivedi³, ¹Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Rheumatology, Amgen, Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
Abstract Number: 995 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Only a Few Expanded T-Cell Clones Dominate in Joint Inflammation: A Study in Seven RA Patients Undergoing Paired Synovial Tissue Biopsies in Multiple Joints
Anne Musters¹, Paul L. Klarenbeek^1,2, Marieke E. Doorenspleet^1,2, Rebecca E.E. Esveldt^1,2, Barbera D.C. van Schaik³, Sander W. Tas^1,2, Antoine H.C. van Kampen³, Frank Baas⁴ and Niek de Vries^1,2, ¹Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Bioinformatics Laboratory, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Previously we found a strong enrichment of highly expanded T-cell clones in rheumatoid arthritis (RA) synovial tissue of inflamed joints. To gain more insight…
Abstract Number: 1640 • 2015 ACR/ARHP Annual Meeting
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Philip J. Mease², Sergio Schwartzman³, Lie-Ju Hwang⁴, Aditya Patel⁵, Koshika Soma⁴, Carol A. Connell⁶, Liza Takiya⁴ and Eustratios Bananis⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Hospital for Special Surgery, New York, NY, ⁴Pfizer Inc, New York, NY, ⁵Inventiv Health Inc, South Plainfield, NJ, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…
Abstract Number: 2696 • 2015 ACR/ARHP Annual Meeting
Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries
Raluca Dumitru¹, Elizabeth M.A. Hensor¹, Ihsane Hmamouchi², Paul Emery³, Maxime Dougados⁴ and Maya H. Buch⁵, ¹University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²El Ayachi Hospital, Rabat, Morocco, ³Academic Section of Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: 28 joints-disease activity score (DAS28) is routinely used in clinical practice to assess disease activity in rheumatoid arthritis (RA). DAS28, particularly its subjective components…
Abstract Number: 2819 • 2014 ACR/ARHP Annual Meeting
The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion
Beatrix Bartok, Division of Rheumatology, allergy and immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Fibroblast like synoviocytes (FLS) in RA possesses unique transformed phenotype, such as cartilage invasion that is maintained independent of cytokines and other inflammatory cells.…
Abstract Number: 1837 • 2014 ACR/ARHP Annual Meeting
First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis
Louise Mercer¹, Xavier Mariette², William Dixon¹, Eva Baecklund³, Karin Hellgren⁴, Lene Dreyer⁵, Merete Lund Hetland⁶, Lene Mellemkjær⁷, Kimme Hyrich⁸, Anja Strangfeld⁹, Angela Zink¹⁰, Helena Canhao¹¹, Fernando Martins¹², Victoria Hernández¹³, Florence Tubach¹⁴, Jacques-Eric Gottenberg¹⁵, Jacques Morel¹⁶, Jakub Zavada¹⁷, Piet van Riel¹⁸, Axel Finckh¹⁹, Florenzo Iannone²⁰, Johan Askling²¹ and Joachim Listing²², ¹The University of Manchester, Manchester, United Kingdom, ²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ³Uppsala University, Uppsala, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁶On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁷Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ¹⁰German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ¹¹Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹²Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹³BIOBADASER Registry, Madrid, Spain, ¹⁴INSERM, Universite Paris Diderot, Paris, France, ¹⁵Department of rheumatology CHU, Strasbourg, France, ¹⁶Universite´ Montpellier, Montpellier, France, ¹⁷Charles University, Prague, Czech Republic, ¹⁸Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²⁰Reumatologia Universita e Policlinico di Bari, Bari, Italy, ²¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²²German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-3 fold increased risk of both Hodgkin and non-Hodgkin lymphoma (HL; NHL). The risk of lymphoma, in…
Abstract Number: 1210 • 2014 ACR/ARHP Annual Meeting
The Role of the Transcription Factor cAMP Responsive Element Binding Protein 1 in Lipopolysaccharide-Induced Tolerance
Kerstin Klein¹, Renate E. Gay², Christoph Kolling³, Lih-Ling Lin⁴, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ³Schulthess Clinic, Zurich, Switzerland, ⁴Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA
Background/Purpose In macrophages, repeated stimulation of Toll-like receptor (TLR) 4 leads to adaptation of signaling pathways and epigenetic modifications resulting in a tolerant state of…
Abstract Number: 444 • 2014 ACR/ARHP Annual Meeting
Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis
Ray A. Ohara¹, Gautam Edhayan¹, Christine M. Ha¹, M. Asif Amin¹, Ali S. Arbab², Phillip L. Campbell³, David A. Fox¹ and Jeffrey H. Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification mediated by peptidyl arginine deiminase (PAD) enzyme in which arginine is converted to citrulline. Inhibitor of DNA binding 1…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Stephen Lindsey¹, Brandi Oufnac² and Holly Walker², ¹Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ²Rheumatology, Ochsner Health Systems, Baton Rouge, LA
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting
Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials
V. Strand¹, S. Ahadieh², J. French³, J. Geier⁴, S. Krishnaswami⁵, S. Menon⁵, T. Checchio², R. Riese⁶ and J. Gomez-Reino⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pharmacometrics, Pfizer Inc, Groton, CT, ³Metrum Research Group, Tariffville, CT, ⁴Pfizer Inc, New York, NY, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Groton, CT, ⁷Hospital Clinico, Universitario de Santiago, Santiago, Spain
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].